Vikram Narayan, MD, on cystectomy outcomes in nadofaragene-treated patients

In this video, Vikram M. Narayan, MD, discusses the background and key findings from the study, “Incidence and pathologic outcomes of cystectomy in patients with bacillus calmette-guérin-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ following treatment with nadofaragene firadenovec-vncg,” which was presented at the Society of Urologic Oncology 25th Annual Meeting in Dallas, Texas. Narayan is an assistant professor of urology at Emory University and the director of urological oncology at Grady Memorial Hospital in Atlanta, Georgia.

Video Transcript:

Could you describe the background/rationale for this study?

This is data from the phase 3 study; it's an analysis that we performed. The phase 3 study, of course, was published in Lancet Oncology a few years ago, which led to the FDA approval of nadofaragene for BCG-unresponsive non–muscle-invasive bladder cancer. What we were interested in understanding was in patients who were on that trial, how many ultimately proceeded to undergo cystectomy, what were the characteristics of those patients, and what was the final pathologic data from patients who ultimately underwent radical cystectomy? What we did was essentially looked at patients followed up through 60 months, and we identified the patients that ultimately did undergo radical cystectomy. Then for patients who had pathologic data available, we performed an analysis on that.

What were the key findings?

Our key finding was among patients who achieved a complete response at 3 months, about 2/3 of patients were able to be cystectomy-free at 60 months. This is a significant number of patients, obviously, who were able to avoid cystectomy. Among those who did undergo cystectomy, we had pathology for about 37 of the I think 44 patients who ultimately underwent cystectomy. Only about 6 patients had muscle-invasive bladder cancer. That's a key take-home as well, because of interest is how many of these patients progress. Now, we don't like the fact that any patient progressed to muscle-invasive bladder cancer, but there's heterogeneity in this patient population. Overall, the take-home message is that in patients with BCG-unresponsive non–muscle-invasive bladder cancer, you can consider nadofaragene as an option among those that are available for treating these patients.

This transcript was AI generated and edited by human editors for clarity.